Fox Chase Cancer Center, Horizon Pharma deal

Horizon and Fox Chase partnered to study Horizon’s Actimmune with PD-1/ PD-L1 inhibitors in cancer, including advanced urothelial and renal cell carcinoma. The first study, which is expected to begi...